Pharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy

References

• Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30(14):1692–1698.
   PubMed Web of Science ®Google Scholar
• Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck: a phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1994;5(6):521–526.
   PubMed Web of Science ®Google Scholar
• Einhorn LH. Curing metastatic testicular cancer. Proc Natl Acad Sci USA. 2002;99:4592–4595.
   PubMed Web of Science ®Google Scholar
• Brock PR, Knight KR, Freyer DR, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol. 2012;30(19):2408–2417.
   PubMed Web of Science ®Google Scholar
• McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 2009;8(1):10–16.
   PubMed Web of Science ®Google Scholar
• Yao X, Panichpisal K, Kurtzman N, et al. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007;334(2):115–124.
   PubMed Web of Science ®Google Scholar
• Shen DW, Pouliot LM, Hall MD, et al. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 2012;64:706–721.
   PubMed Web of Science ®Google Scholar
• Safirstein R, Miller P, Guttenplan JB. Uptake and metabolism of cisplatin by rat kidney. Kidney Int. 1984;25(5):753–758.
   PubMed Web of Science ®Google Scholar
• Akcay A, Turkmen K, Lee D, et al. Update on the diagnosis and management of acute kidney injury. Int J Nephrol Renovasc Dis. 2010;3:129–140.
   PubMedGoogle Scholar
• Schilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med. 1979;90:929–931.
   PubMed Web of Science ®Google Scholar
• Cornelison TL, Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol. 1993;50:147–158.
   PubMed Web of Science ®Google Scholar
• Rybak LP, Whitworth CA, Mukherjea D, et al. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res. 2007;226:157–167.
   PubMed Web of Science ®Google Scholar
• Laurell G, Ekborn A, Viberg A, et al. Effects of a single high dose of cisplatin on the melanocytes of the stria vascularis in the guinea pig. Audiol Neurootol. 2007;12:170–178.
   PubMed Web of Science ®Google Scholar
• Hellberg V, Gahm C, Liu W, et al. Immunohistochemical localization of OCT2 in the cochlea of various species. Laryngoscope. 2015;125(9):E320–5.
   PubMedGoogle Scholar
• Lanvers-Kaminsky C, Sprowl JA, Malath I, et al. Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity. Pharmacogenomics. 2015;16:323–332.
   PubMed Web of Science ®Google Scholar
• Ciarimboli G, Deuster D, Knief A, et al. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol. 2010;176:1169–1180.
   PubMed Web of Science ®Google Scholar
• More SS, Akil O, Ianculescu AG, et al. Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J Neurosci. 2010;30:9500–9509.
   PubMed Web of Science ®Google Scholar
• Albers JW, Chaudhry V, Cavaletti G, et al. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2014;3:CD005228.
   PubMed Web of Science ®Google Scholar
• Roelofs RI, Hrushesky W, Rogin J, et al. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology (Minneap). 1984;34:934–938.
   PubMed Web of Science ®Google Scholar
• Slattery EL, Oshima K, Heller S, et al. Cisplatin exposure damages resident stem cells of the mammalian inner ear. Dev Dyn. 2014;243:1328–1337.
   PubMed Web of Science ®Google Scholar
• Khynriam D, Prasad SB. Changes in glutathione-related enzymes in tumor-bearing mice after cisplatin treatment. Cell Biol Toxicol. 2002;18:349–358.
   PubMed Web of Science ®Google Scholar
• Sadzuka Y, Shoji T, Takino Y. Mechanism of the increase in lipid peroxide induced by cisplatin in the kidneys of rats. Toxicol Lett. 1992;62:293–300.
   PubMed Web of Science ®Google Scholar
• Kruidering M, Van De Water B, De Heer E, et al. Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J Pharmacol Exp Ther. 1997;280:638–649.
   PubMed Web of Science ®Google Scholar
• Campbell KC, Rybak LP, Meech RP, et al. D-methionine provides excellent protection from cisplatin ototoxicity in the rat. Hear Res. 1996;102:90–98.
   PubMed Web of Science ®Google Scholar
• Dickey DT, Wu YJ, Muldoon LL, et al. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther. 2005;314:1052–1058.
   PubMed Web of Science ®Google Scholar
• Ramesh G, Reeves WB. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol. 2005;289:F166–74.
   PubMed Web of Science ®Google Scholar
• Pabla N, Murphy RF, Liu K, et al. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol. 2009;296:F505–F511.
   PubMed Web of Science ®Google Scholar
• Filipski KK, Mathijssen RH, Mikkelsen TS, et al. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther. 2009;86:396–402.
   PubMed Web of Science ®Google Scholar
• Juo P, Kuo CJ, Yuan J, et al. Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr Biol. 1998;8:1001–1008.
   PubMed Web of Science ®Google Scholar
• Srinivasula SM, Ahmad M, Fernandes-Alnemri T, et al. Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases. Proc Natl Acad Sci USA. 1996;93:14486–14491.
   PubMed Web of Science ®Google Scholar
• Lee RH, Song JM, Park MY, et al. Cisplatin-induced apoptosis by translocation of endogenous Bax in mouse collecting duct cells. Biochem Pharmacol. 2001;62:1013–1023.
   PubMed Web of Science ®Google Scholar
• Jiang M, Wei Q, Wang J, et al. Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis. Oncogene. 2006;25:4056–4066.
   PubMed Web of Science ®Google Scholar
• Seth R, Yang C, Kaushal V, et al. p53-dependent caspase-2 activation in mitochondrial release of apoptosis-inducing factor and its role in renal tubular epithelial cell injury. J Biol Chem. 2005;280:31230–31239.
   PubMed Web of Science ®Google Scholar
• Cummings BS, Schnellmann RG. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J Pharmacol Exp Ther. 2002;302:8–17.
   PubMed Web of Science ®Google Scholar
• Price PM, Safirstein RL, Megyesi J. Protection of renal cells from cisplatin toxicity by cell cycle inhibitors. Am J Physiol Renal Physiol. 2004;286:F3378–84.
   Google Scholar
• Yu F, Megyesi J, Safirstein RL, et al. Identification of the functional domain of p21(WAF1/CIP1) that protects cells from cisplatin cytotoxicity. Am J Physiol Renal Physiol. 2005;289:F514–20.
   Google Scholar
• Arany I, Megyesi JK, Kaneto H, et al. Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am J Physiol Renal Physiol. 2004;287:F543–49.
   PubMed Web of Science ®Google Scholar
• Mishima K, Baba A, Matsuo M, et al. Protective effect of cyclic AMP against cisplatin-induced nephrotoxicity. Free Radic Biol Med. 2006;40:1564–1577.
   PubMed Web of Science ®Google Scholar
• Francescato HD, Costa RS, Junior FB, et al. Effect of JNK inhibition on cisplatin-induced renal damage. Nephrol Dial Transpl. 2007;22:2138–2148.
   PubMed Web of Science ®Google Scholar
• Tsuruya K, Ninomiya T, Tokumoto M, et al. Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney Int. 2003;63:72–82.
   PubMed Web of Science ®Google Scholar
• Liu H, Baliga R. Endoplasmic reticulum stress-associated caspase 12 mediates cisplatin-induced LLC-PK1 cell apoptosis. J Am Soc Nephrol. 2005;16:1985–1992.
   PubMed Web of Science ®Google Scholar
• Laurell G, Engstrom B. The combined effect of cisplatin and furosemide on hearing function in guinea pigs. Hear Res. 1989;38:19–26.
   PubMed Web of Science ®Google Scholar
• Thomas AJ, Hailey DW, Stawicki TM, et al. Functional mechanotransduction is required for Cisplatin-induced hair cell death in the zebrafish lateral line. J Neurosci. 2013;33:4405–4414.
   PubMed Web of Science ®Google Scholar
• Alharazneh A, Luk L, Huth M, et al. Functional hair cell mechanotransducer channels are required for aminoglycoside ototoxicity. PLoS One. 2011;6:e22347.
   PubMed Web of Science ®Google Scholar
• Farris HE, LeBlanc CL, Goswami J, et al. Probing the pore of the auditory hair cell mechanotransducer channel in turtle. J Physiol. 2004;558:769–792.
   PubMed Web of Science ®Google Scholar
• Marcotti W, Van Netten SM, Kros CJ. The aminoglycoside antibiotic dihydrostreptomycin rapidly enters mouse outer hair cells through the mechano-electrical transducer channels. J Physiol. 2005;567:505–521.
   PubMed Web of Science ®Google Scholar
• Vu AA, Nadaraja GS, Huth ME, et al. Integrity and regeneration of mechanotransduction machinery regulate aminoglycoside entry and sensory cell death. PLoS One. 2013;8:e54794.
   Google Scholar
• Hilder TA, Hill JM. Modelling the encapsulation of the anticancer drug cisplatin into carbon nanotubes. Nanotechnology. 2007;18:275704.
   Web of Science ®Google Scholar
• Berger K, Moeller MJ. Mechanisms of epithelial repair and regeneration after acute kidney injury. Semin Nephrol. 2014;34:394–403.
   PubMed Web of Science ®Google Scholar
• Karasawa T, Steyger PS. An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett. 2015;237(3):219–227.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Lee JH, Kim SJ. Roles of NADPH oxidases in cisplatin-induced reactive oxygen species generation and ototoxicity. J Neurosci. 2010;30:3933–3946.
   PubMed Web of Science ®Google Scholar
• Mukherjea D, Jajoo S, Whitworth C, et al. Short interfering RNA against transient receptor potential vanilloid 1 attenuates cisplatin-induced hearing loss in the rat. J Neurosci. 2008;28:13056–13065.
   PubMed Web of Science ®Google Scholar
• Schmitt NC, Rubel EW, Nathanson NM. Cisplatin-induced hair cell death requires STAT1 and is attenuated by epigallocatechin gallate. J Neurosci. 2009;29:3843–3851.
   PubMed Web of Science ®Google Scholar
• Devarajan P, Savoca M, Castaneda MP. Cisplatin-induced apoptosis in auditory cells: role of death receptor and mitochondrial pathways. Hear Res. 2002;174:45–54.
   PubMed Web of Science ®Google Scholar
• Zhang M, Liu W, Ding D, et al. Pifithrin-alpha suppresses p53 and protects cochlear and vestibular hair cells from cisplatin-induced apoptosis. Neuroscience. 2003;120:191–205.
   PubMed Web of Science ®Google Scholar
• Mukherjea D, Jajoo S, Sheehan K, et al. NOX3 NADPH oxidase couples transient receptor potential vanilloid 1 to signal transducer and activator of transcription 1-mediated inflammation and hearing loss. Antioxid Redox Signal. 2011;14:999–1010.
   PubMed Web of Science ®Google Scholar
• Kaur T, Mukherjea D, Sheehan K, et al. Short interfering RNA against STAT1 attenuates cisplatin-induced ototoxicity in the rat by suppressing inflammation. Cell Death Dis. 2011;2:e180.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Inai S, Jinnouchi K, et al. Nuclear-factor kappa B (NF-kappa B)-inducible nitric oxide synthase (iNOS/NOSII) pathway damages the stria vascularis in cisplatin-treated mice. Anticancer Res. 2002;22:4081–4085.
   PubMed Web of Science ®Google Scholar
• Li G, Liu W, Frenz D. Cisplatin ototoxicity to the rat inner ear: a role for HMG1 and iNOS. Neurotoxicology. 2006;27:22–30.
   PubMed Web of Science ®Google Scholar
• Avan A, Postma TJ, Ceresa C, et al. Platinum-induced neurotoxicity and preventive strategies: past, present, and future. Oncologist. 2015;20(4):411–432.
   PubMed Web of Science ®Google Scholar
• Dzagnidze A, Katsarava Z, Makhalova J, et al. Repair capacity for platinum-DNA adducts deter-mines the severity of cisplatin-induced peripheral neuropathy. J Neurosci. 2007;27:9451–9457.
   PubMed Web of Science ®Google Scholar
• Englander EW. DNA damage response in peripheral nervous system: coping with cancer therapy-induced DNA lesions. DNA Rep (Amst). 2013;12:685–690.
   PubMed Web of Science ®Google Scholar
• Furuta T, Ueda T, Aune G, et al. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 2002;62:3899–4902.
   Google Scholar
• Jiang Y, Guo C, Vasko MR, et al. Implications of apurinic/apyrimidinic endonuclease in reactive oxygen signaling response after cisplatin treatment of dorsal root ganglion neurons. Cancer Res. 2008;68:6425–6434.
   PubMed Web of Science ®Google Scholar
• Clayton DA. Replication and transcription of vertebrate mitochondrial DNA. Annu Rev Cell Biol. 1991;7:453–478.
   PubMedGoogle Scholar
• Croteau DL, Stierum RH, Bohr VA. Mitochondrial DNA repair pathways. Mutat Res. 1999;434:137–148.
   PubMed Web of Science ®Google Scholar
• Züchner S, Mersiyanova IV, Muglia M, et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2. Nat Genet. 2004;36:449–451.
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Sonka S, Stevenson LL, et al. Progressive paresthesias after cessation of therapy with very high-dose cisplatin. Cancer Chemother Pharmacol. 1989;25:62–64.
   PubMed Web of Science ®Google Scholar
• Roila F, Ballatori E, Tonato M, et al. 5-HT3 receptor antagonists: differences and similarities. Eur J Cancer. 1997;33:1364–1370.
   PubMed Web of Science ®Google Scholar
• Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron, compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 2006;17:1441–1449.
   PubMed Web of Science ®Google Scholar
• Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009;10:115–124.
   PubMed Web of Science ®Google Scholar
• Hashimoto H, Yamanaka T, Shimada Y, et al. Palonosetron versus granisetron in the triplet regimen with dexamethasone and aprepitant for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy with cisplatin: a randomized, double-blind, phase III trial. J Clin Oncol. 2013;31:605s. abstract 9621.
   Google Scholar
• Mantyh PW. Neurobiology of substance P and the NK1 receptor. J Clin Psychiatry. 2002;63(Suppl 11):6–10.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ. Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting. Support Care Cancer. 2001;9:350–354.
   PubMed Web of Science ®Google Scholar
• Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer. 2003;97:3090–3098.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – The Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21:4112–4119.
   PubMed Web of Science ®Google Scholar
• Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study Protocol-EASE. J Clin Oncol. 2011;29:1495–1501.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014;25(7):1340–1346.
   PubMed Web of Science ®Google Scholar
• Rapoport BL, Chasen MR, Gridelli C, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol. 2015;16(9):1079–1089.
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS, Modiano MR, Rapoport BL, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol. 2015;16(9):1071–1078.
   PubMed Web of Science ®Google Scholar
• Sprowl JA, van Doorn L, Hu S, et al. Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance. Clin Pharmacol Ther. 2013;94:585–592.
   PubMed Web of Science ®Google Scholar
• Chang Panesso M, Shi M, Cho HJ, et al. Klotho has dual protective effects on cisplatin-induced acute kidney injury. Kidney Int. 2014;85(4):855–870.
   PubMed Web of Science ®Google Scholar
• Popivanova BK, Kitamura K, Wu Y, et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest. 2008;118:560–570.
   PubMed Web of Science ®Google Scholar
• Deng J, Kohda Y, Chiao H, et al. Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int. 2001;60:2118–2128.
   PubMed Web of Science ®Google Scholar
• Mukherjea D, Jajoo S, Kaur T, et al. Transtympanic administration of short interfering (si)RNA for the NOX3 isoform of NADPH oxidase protects against cisplatin-induced hearing loss in the rat. Antioxid Redox Signal. 2010;13:589–598.
   PubMed Web of Science ®Google Scholar
• Roy S, Ryals MM, Van den Bruele AB, et al Sound preconditioning therapy inhibits ototoxic hearing loss in mice. J Clin Invest. 2013;123:4945–4949.
   PubMed Web of Science ®Google Scholar
• De Santis S, Pace A, Bove L, et al. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clin Cancer Res. 2000;6:90–95.
   PubMed Web of Science ®Google Scholar
• Schmidt Y, Unger JW, Bartke I, et al. Effect of nerve growth factor on peptide neurons in dorsal root ganglia after taxol or cisplatin treatment and in diabetic (db/db) mice. Exp Neurol. 1995;132:16–23.
   PubMed Web of Science ®Google Scholar
• Scuteri A, Galimberti A, Ravasi M, et al. NGF protects dorsal root ganglion neurons from oxaliplatin by modulating JNK/Sapk and ERK1/2. Neurosci Lett. 2010;486:141–145.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Jenison EL, Kim K, et al. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol. 1997;67:172–177.
   PubMed Web of Science ®Google Scholar
• van der Hoop RG, Vecht CJ, van der Burg ME, et al. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med. 1990;322:89–94.
   PubMed Web of Science ®Google Scholar
• Arrieta O, Garcia-Navarrete R, Zuñiga S, et al. Retinoic acid increases tissue and plasma contents of nerve growth factor and prevents neuropathy in diabetic mice. Eur J Clin Invest. 2005;35:201–207.
   PubMed Web of Science ®Google Scholar
• Arrieta Ó, Hernández-Pedro N, Fernández-González-Aragón MC, et al. Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer. Neurology. 2011;77(10):987–995.
   PubMed Web of Science ®Google Scholar
• DiPaola RS, Schuchter L. Neurologic protection by amifostine. Semin Oncol. 1999;26(suppl 7):82–88.
   PubMed Web of Science ®Google Scholar
• Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol. 1996;14(7):2101–2112.
   PubMed Web of Science ®Google Scholar
• Rose PG. Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma. Semin Oncol. 1996;23(4 Suppl 8):83–89.
   PubMed Web of Science ®Google Scholar
• Lu P, Fan QX, Wang LX, et al. Prophylactic effect of amifostine on oxaliplatin-related neuro-toxicity in patients with digestive tract tumors. Ai Zheng. 2008;27:1117–1120.
   PubMedGoogle Scholar
• Valenzuela A, Garrido A. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biol Res. 1994;27(2):105–112.
   PubMedGoogle Scholar
• Momeni A, Hajigholami A, Geshnizjani S, et al. Effect of silymarin in the prevention of cisplatin nephrotoxicity, a clinical trial study. J Clinl Diagn Res. 2015;9(4):OC11–OC13.
   PubMed Web of Science ®Google Scholar
• Smyth JF, Bowman A, Perren T, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Ann Oncol. 1997;8:569–573.
   PubMed Web of Science ®Google Scholar
• Cascinu S, Cordella L, Del Ferro E, et al. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol. 1995;13:26–32.
   PubMed Web of Science ®Google Scholar
• Bogliun G, Marzorati L, Cavaletti G, et al. Evaluation by somatosensory evoked potentials of the neurotoxicity of cisplatin alone or in combination with glutathione. Ital J Neurol Sci. 1992;13:643–647.
   PubMedGoogle Scholar
• Kottschade LA, Sloan JA, Mazurczak MA, et al. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care Cancer. 2011;19:1769–1777.
   PubMed Web of Science ®Google Scholar
• Pace A, Giannarelli D, Galie E, et al. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Neurology. 2010;74:762–766.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Chroni E, Koutras A, et al. A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. Support Care Cancer. 2006;14:1134–1140.
   PubMed Web of Science ®Google Scholar
• Pace A, Savarese A, Picardo M, et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol. 2003;21:927–931.
   PubMed Web of Science ®Google Scholar
• Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309:1359–1367.
   PubMed Web of Science ®Google Scholar
• Rao RD, Michalak JC, Sloan JA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007;110:2110–2118.
   PubMed Web of Science ®Google Scholar
• Saif MW, Syrigos K, Kaley K, et al. Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Res. 2010;30(7):2927–2933.
   PubMed Web of Science ®Google Scholar
• Kidera Y, Kawakami H, Sakiyama T, et al. Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PLoS One. 2014;9(7):e101902.
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Berger CC, Hartmann JT, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer. 1998;77:1355–1362.
   PubMed Web of Science ®Google Scholar
• Caronia D, Patino-Garcia A, Milne RL, et al. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J. 2009;9:347–353.
   PubMed Web of Science ®Google Scholar
• Suk R, Gurubhagavatula S, Park S, et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res. 2005;11:1534–1538.
   PubMed Web of Science ®Google Scholar
• Carleton B, Poole R, Smith M, et al. Adverse drug reaction active surveillance: developing a national network in Canada’s children’s hospitals. Pharmacoepidemiol Drug Saf. 2009;18:713–721.
   PubMed Web of Science ®Google Scholar
• Ross CJ, Katzov-Eckert H, Dube MP, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet. 2009;41:1345–1349.
   PubMed Web of Science ®Google Scholar
• Xu H, Robinson GW, Huang J, et al. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nat Genet. 2015;47:263–266.
   PubMed Web of Science ®Google Scholar
• Koo JW, Quintanilla-Dieck L, Jiang M, et al. Endotoxemia-mediated inflammation potentiates aminoglycoside-induced ototoxicity. Sci Transl Med. 2015;7(298):298ra118.
   PubMed Web of Science ®Google Scholar
• Oh GS, Kim HJ, Choi JH, et al. Activation of lipopolysaccharide-TLR4 signaling accelerates the ototoxic potential of cisplatin in mice. J Immunol. 2011;186:1140–1150.
   PubMed Web of Science ®Google Scholar
• Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro-oncol. 2012;14(suppl 4):iv45–iv54.
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med. 1993;329:1790–1796.
   PubMed Web of Science ®Google Scholar